Edaglitazone

Pricing Availability   Qty
Cat.No. 4784 - Edaglitazone | C24H20N2O4S2 | CAS No. 213411-83-7
Description: Potent and selective PPARγ agonist; antidiabetic
Alternative Names: R 483, BM 131258
Chemical Name: 5-[[4-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]benzo[b]thien-7-yl]methyl]-2,4-thiazolidinedione
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Potent and selective PPARγ agonist (EC50 values are 35.6 and 1053 nM for PPARγ and PPARα cofactor recruitment respectively. Enhances insulin sensitivity in obese, but not lean, rats. Antidiabetic and orally bioavailable.

Compound Libraries

Edaglitazone is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 464.56
Formula C24H20N2O4S2
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 213411-83-7
PubChem ID 9825701
InChI Key HAAXAFNSRADSMK-UHFFFAOYSA-N
Smiles CC(OC(C5=CC=CC=C5)=N4)=C4CCOC(C3=C2SC=C3)=CC=C2CC1C(NC(S1)=O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solubility Soluble to 100 mM in DMSO

References

References are publications that support the biological activity of the product.

Fürnsinn et al (1999) Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br. J. Pharmacol. 128 1141 PMID: 10578125

Dietz et al (2012) Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem 7 1101 PMID: 22489042


If you know of a relevant reference for Edaglitazone, please let us know.

View Related Products by Target

View Related Products by Product Action

View all PPARγ Agonists

Keywords: Edaglitazone, Edaglitazone supplier, potent, selective, peroxisome, proliferator-activated, receptors, PPARgamma, PPARg, PPARγ, agonists, diabetes, antidiabetics, R483, BM131258, insulin, sensitizers, R, 483, BM, 131258, Receptors, 4784, Tocris Bioscience

Citations for Edaglitazone

Citations are publications that use Tocris products.

Currently there are no citations for Edaglitazone. Do you know of a great paper that uses Edaglitazone from Tocris? Please let us know.

Reviews for Edaglitazone

There are currently no reviews for this product. Be the first to review Edaglitazone and earn rewards!

Have you used Edaglitazone?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Nuclear Receptors

Nuclear Receptors Product Listing

A collection of over 150 products for key nuclear receptors, the listing includes research tools for the study of:

  • Androgen Receptors
  • Estrogen Receptors
  • Retinoic Acid Receptors
  • Retinoid X Receptors
  • Vitamin D Receptors
Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.